ArticleBMC cancer2025
Prevalence and therapeutic response of EGFR T790I mutation in NSCLC patients with acquired resistance to EGFR-TKIs: a retrospective cohort study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe EGFR T790I mutation is a potential resistance mechanism against EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). However, its prevalence and clinical significance remain unexplored. We aim to delineate the mutational spectrum of EGFR T790I in NSCLC patients and investigate its association with clinical outcomes and resistance to EGFR-targeted therapies.
methodsWe retrospectively reviewed the clinico-genomic databases of Chinese NSCLC patients who underwent next-generation sequencing (NGS) at Geneseeq from January 2017 to June 2024. The clinicopathological features and treatment histories of patients harboring the EGFR T790I mutation were analyzed.
resultsThe EGFR T790I mutation was exclusively observed in patients previously treated with EGFR-TKIs. Among those who developed resistance to first- or second-generation TKIs, six (0.054%) patients had the T790I mutation. All six cases exhibited concurrent EGFR L858R mutations and no other sensitizing mutations were detected. Notably, the T790I mutation was identified in various sample types, including tissue, plasma and pleura effusion samples, collected post-progression on EGFR-TKIs. In matched pre- and post-treatment samples from two patients, T790I was newly acquired post resistance to first-generation EGFR-TKI therapies. Two patients benefited from osimertinib, suggesting its activity against T790I-induced resistance.
conclusionsThese findings underscore the importance of continuous genetic monitoring and personalized therapeutic strategies. While the T790I mutation is rare, its significant implications for disease progression and treatment resistance warrant further exploration and targeted intervention of third-generation inhibitors like osimertinib.
trial registrationretrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.